vs
Alpha Cognition Inc.（ACOG）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Alpha Cognition Inc.的288.4倍（$805.5M vs $2.8M）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -245.5%，领先264.6%）。NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $-7.1M）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
ACOG vs NBIX — 直观对比
营收规模更大
NBIX
是对方的288.4倍
$2.8M
净利率更高
NBIX
高出264.6%
-245.5%
自由现金流更多
NBIX
多$393.1M
$-7.1M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8M | $805.5M |
| 净利润 | $-6.9M | $153.7M |
| 毛利率 | — | 97.8% |
| 营业利润率 | -283.7% | 26.2% |
| 净利率 | -245.5% | 19.1% |
| 营收同比 | — | 28.3% |
| 净利润同比 | — | 49.1% |
| 每股收益（稀释后） | $-0.10 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACOGNBIX
| Q4 25 | $2.8M | $805.5M | ||
| Q3 25 | $2.8M | $794.9M | ||
| Q2 25 | $1.7M | $687.5M | ||
| Q1 25 | $2.9M | $572.6M | ||
| Q4 24 | — | $627.7M | ||
| Q3 24 | — | $622.1M | ||
| Q2 24 | — | $590.2M | ||
| Q1 24 | — | $515.3M |
净利润ACOGNBIX
| Q4 25 | $-6.9M | $153.7M | ||
| Q3 25 | $-1.3M | $209.5M | ||
| Q2 25 | $-10.5M | $107.5M | ||
| Q1 25 | $-2.0M | $7.9M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $129.8M | ||
| Q2 24 | — | $65.0M | ||
| Q1 24 | — | $43.4M |
毛利率ACOGNBIX
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | 96.7% | 98.4% | ||
| Q1 25 | 99.6% | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 98.5% |
营业利润率ACOGNBIX
| Q4 25 | -283.7% | 26.2% | ||
| Q3 25 | -187.0% | 30.1% | ||
| Q2 25 | -346.1% | 21.2% | ||
| Q1 25 | -125.9% | 4.1% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | — | 29.5% | ||
| Q2 24 | — | 24.6% | ||
| Q1 24 | — | 19.3% |
净利率ACOGNBIX
| Q4 25 | -245.5% | 19.1% | ||
| Q3 25 | -46.4% | 26.4% | ||
| Q2 25 | -632.7% | 15.6% | ||
| Q1 25 | -68.5% | 1.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | — | 20.9% | ||
| Q2 24 | — | 11.0% | ||
| Q1 24 | — | 8.4% |
每股收益（稀释后）ACOGNBIX
| Q4 25 | $-0.10 | $1.49 | ||
| Q3 25 | $-0.30 | $2.04 | ||
| Q2 25 | $-0.65 | $1.06 | ||
| Q1 25 | $-0.13 | $0.08 | ||
| Q4 24 | — | $1.00 | ||
| Q3 24 | — | $1.24 | ||
| Q2 24 | — | $0.63 | ||
| Q1 24 | — | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.0M | $713.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $62.5M | $3.3B |
| 总资产 | $79.7M | $4.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACOGNBIX
| Q4 25 | $66.0M | $713.0M | ||
| Q3 25 | $35.4M | $340.2M | ||
| Q2 25 | $39.4M | $264.0M | ||
| Q1 25 | $45.5M | $194.1M | ||
| Q4 24 | — | $233.0M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $139.7M | ||
| Q1 24 | — | $396.3M |
股东权益ACOGNBIX
| Q4 25 | $62.5M | $3.3B | ||
| Q3 25 | $33.9M | $3.0B | ||
| Q2 25 | $31.9M | $2.7B | ||
| Q1 25 | $40.8M | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.4B |
总资产ACOGNBIX
| Q4 25 | $79.7M | $4.6B | ||
| Q3 25 | $46.3M | $4.3B | ||
| Q2 25 | $45.1M | $3.9B | ||
| Q1 25 | $48.6M | $3.7B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.5B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.9M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $-7.1M | $386.0M |
| 自由现金流率自由现金流/营收 | -252.6% | 47.9% |
| 资本支出强度资本支出/营收 | 5.3% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | $-20.7M | $743.9M |
8季度趋势，按日历期对齐
经营现金流ACOGNBIX
| Q4 25 | $-6.9M | $388.4M | ||
| Q3 25 | $-5.3M | $227.5M | ||
| Q2 25 | $-6.1M | $102.0M | ||
| Q1 25 | $-2.0M | $64.8M | ||
| Q4 24 | — | $242.5M | ||
| Q3 24 | — | $158.0M | ||
| Q2 24 | — | $64.6M | ||
| Q1 24 | — | $130.3M |
自由现金流ACOGNBIX
| Q4 25 | $-7.1M | $386.0M | ||
| Q3 25 | $-5.4M | $214.3M | ||
| Q2 25 | $-6.1M | $89.5M | ||
| Q1 25 | $-2.1M | $54.1M | ||
| Q4 24 | — | $235.2M | ||
| Q3 24 | — | $149.9M | ||
| Q2 24 | — | $53.0M | ||
| Q1 24 | — | $119.1M |
自由现金流率ACOGNBIX
| Q4 25 | -252.6% | 47.9% | ||
| Q3 25 | -188.8% | 27.0% | ||
| Q2 25 | -370.9% | 13.0% | ||
| Q1 25 | -72.0% | 9.4% | ||
| Q4 24 | — | 37.5% | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | 23.1% |
资本支出强度ACOGNBIX
| Q4 25 | 5.3% | 0.3% | ||
| Q3 25 | 2.6% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 2.2% | 1.9% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.0% | ||
| Q1 24 | — | 2.2% |
现金转化率ACOGNBIX
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACOG
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
